Scholarlink

Treatments targeting JAK inhibitors can be used in two ways as oral and topical. JAK inhibitors currently used topically are tofacitinib, ruxolitinib, delgocitinib and brepocitinib. In this section, the properties of topical janus kinase inhibitors and the dermatological diseases in which they are used, atopic dermatitis, vitiligo, alopecia areata and psoriasis vulgaris will be discussed.

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Topikal JAK Inhibitors

  • 章节

  • 发表日期：

    2025年

查看全文
  • Atıl Avcı,
  • Ragıp Ertaş

摘要

Treatments targeting JAK inhibitors can be used in two ways as oral and topical. JAK inhibitors currently used topically are tofacitinib, ruxolitinib, delgocitinib and brepocitinib. In this section, the properties of topical janus kinase inhibitors and the dermatological diseases in which they are used, atopic dermatitis, vitiligo, alopecia areata and psoriasis vulgaris will be discussed.